Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Eliprodil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.98 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.98 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.98 |
| ▸ | TP53 | P04637 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | TSHR | P16473 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | THPO | P40225 | 1/20 | 0.98 |
| ▸ | MTOR | P42345 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CCR3 | P51677 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eliprodil SCHEMBL7525726 | 1.00 | GMNN (0.98) | GMNNTP53CYP3A4ALOX15TSHR | |
| Eliprodil SCHEMBL7521721 | 1.00 | GMNN (0.98) | GMNNTP53CYP3A4ALOX15TSHR | |
| Eliprodil SCHEMBL154047 | 0.99 | GMNN (1.00) | GMNNTP53CYP3A4ALOX15TSHR | |
| Eliprodil SCHEMBL7517402 | 0.99 | GMNN (1.00) | GMNNTP53CYP3A4ALOX15TSHR | |
| Eliprodil SCHEMBL6254237 | 0.99 | GMNN (1.00) | GMNNTP53CYP3A4ALOX15TSHR | |
| SCHEMBL10732857 | 0.86 | MEN1 (0.82) | GMNNTP53CYP3A4ALOX15TSHR | |
| SCHEMBL21614247 | 0.84 | GMNN (0.74) | GMNNTP53CYP3A4ALOX15TSHR | |
| SCHEMBL467199 | 0.84 | GRIN2B (0.73) | GMNNTP53CYP3A4ALOX15TSHR | |
| SCHEMBL9258826 | 0.83 | GRIN1 (0.73) | GMNNTP53CYP3A4ALOX15TSHR | |
| Ifenprodil SCHEMBL1725512 | 0.82 | GRIN2B (0.69) | GMNNTP53CYP3A4ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0718407-B1 | Intermediates for the synthesis of eliprodil enantiomers and process for their preparation | SANOFI SYNTHELABO (FR) | 2002-02-13 | — | — | EP | claimed |
| US-6509355-B1 | This invention is directed to the use of glutamate antagonists to treat the disorders of outer retina. The pathogenesis of retinal degenerative diseases such as age- related macular degeneration (ARMD) and retinitis pigmentosa (RP) is | ALCON LABORATORIES, INC. | 2003-01-21 | — | — | US | disclosed |
| US-6291479-B1 | Use of NR2B-selective NMDA-receptor antagonists for the treatment of ophthalmic diseases | ALCON MANUFACTURING, LTD. | 2001-09-18 | — | — | US | disclosed |
| US-6200990-B1 | 4-PHENYLPIPERIDIN-1-YLETHANOL DERIVATIVES; VISION DEFECTS, BRAIN AND SPINAL CORD INJURIES | ALCON LABORATORIES, INC. | 2001-03-13 | — | — | US | disclosed |
| US-5965534-A | ADMINISTERING OMEGA-CONOTOXIN INTRAOCULARLY TO HUMAN FOR PROPHYLAXIS AND TRATEMENT OF RETINAL OR OPTIC NERVE HEAD DAMAGE RESULTING FROM ACUTE TRAUMATIC OR ISCHEMIC EVENTS | ALCON LABORATORIES, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5652248-A | Method of preventing peripheral neuropathies induced by anticancer agents | SYNTHELABO (FR) | 1997-07-29 | — | — | US | disclosed |